No Data
OBIO Celebrates 15th Anniversary With Fresh New Look
Express News | HuaYuan Bioscience: Shareholders intend to collectively reduce their shareholding by no more than 3.2%.
OBIO and CATTI Collaborate to Boost Canada's Biomanufacturing Capacity for Advanced Therapies
The first gene therapy CDMO stock cannot break out of the loss "vortex"! HUYA Bio had a net loss of 0.19 billion in the first three quarters.
①He Yuan Biology is still deeply mired in the vortex of losses, with a net loss of 0.19 billion yuan attributable to owners in the first three quarters of this year, a year-on-year decrease of 166.90%, compared to a net loss of 71.0996 million yuan in the same period last year. ②He Yuan Biology revealed that customers are more price sensitive due to limited financing, and the prices of different types of CDMO orders are at historically low levels.
Heyuan Biotech: Report for the third quarter of 2024
Third Quarter Report 2024
No Data
